Vertex also reported a steady increase in its R&D and SG&A expenses, reflecting its aggressive investment in pipeline ...

Both stocks have made significant breakthroughs. Among the qualities a biotech company needs to be successful, being innovative is one of the most important. It's easy to understand why. Although ...

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment ...

Andrew Fein has given his Buy rating due to a combination of factors that highlight Vertex Pharmaceuticals’ potential success with its drug candidate suzetrigine. The drug’s mechanism of action, which ...

Operator Good day, and welcome to the Vertex Pharmaceuticals third quarter 2024 earnings call. All participants will be in a ...

Companies announce stock splits all the time, and so far this year a number of high profile companies have divvied up their ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

Vertex Pharmaceuticals raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its ...

Vertex is approaching two key PDUFA dates in January for new treatments in cystic fibrosis and pain respectively.

The No Pain Act will mandate Medicare insurance coverage for non-opioid pain management, including evidence-based treatments, ...

Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals (NASDAQ:VRTX). And retail traders should know. We noticed this today when the trades showed up on ...

Nov 4 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new ... Sales of Vertex's top-selling CF drug Trikafta rose more than 13% to $2.59 billion for the quarter ended Sept.